The European anticoccidial drugs market size is estimated to grow from 211.74 million in 2021 to USD 244.15 Million by 2026 at a CAGR of 2.89%.
Growing incidences of infectious diseases in animals are sole to surge growth opportunities for the market. Anticoccidial drugs play a vital role in treating coccidial diseases, most common in animals and birds. Pharmaceutical companies have entirely focused on preventing or controlling diseases by manufacturing new drugs with high quality and creating chances for the market to grow. The rise in the demand for meat and poultry products is expanding the growth of the market.
Growing awareness over the availability of the drugs even in rural areas is lavishing the growth of the market in Europe. In many areas, the anticoccidial drugs are considered a remedy in preventing diseases like ailment inflicting protozoa is ascribed to outshine the demand of the market extensively. Increasing livestock diseases is also an attribute leveling up the growth of the market. Maintaining proper feeding for the animals will process good health, which is additionally fueling the demand of the market.
Furthermore, increasing the scale of research and development institutes shows an immense growth rate for the market. Stringent rules and regulations by the government regarding the safety of animals and birds are lucratively propelling the demand of the market.
This research report on European Anticoccidial Drugs Market has been segmented and sub-segmented into the following categories:
By Drug Type:
By Animals:
By Country
Regionally, Spain is witnessed in leading with the highest shares of the market by the quick adoption of the latest technologies and innovative techniques in preventing various diseases. Along with this, growing support from the government through investments in pharmaceutical companies is magnifying the growth rate of the market. The increasing consumption rate of meat products from the past few years is to gear up the market demand in this country.
UK and Italy are standing next to Spain in holding dominant shares of the market. The rise in the various health disorders in animals is broadening the demand of the market. Also, positive economic growth in these countries is vital to point for the market to grow.
Germany is accounted for in having a tremendous growth rate from the past few years and is also expected to have significant growth throughout the forecast period. The increasing number of veterinary hospitals with pharmacies is gaining traction over the shares of the Europan anticoccidial drugs market.
France is esteemed to have significant growth opportunities shortly with the rise in awareness over the manufacturing of drugs with appropriate concentrations.
Notable companies dominating the European anticoccidial drugs market are Bayer Health care, Boehringer Ingelheim Animal Health, Elanco, Merial, Merck Animal Healthcare, Virbac, Zoetis, Ceva Santé Animale, Novartis Animal Healthcare, and Smartvet Inc.
The industry's major players are facing various challenges related to microbial resistance build-up to therapeutics and government regulations in the European Union. For this reason, many companies prefer to operate in less regulated markets.
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Analysis Design
2.3 Research Phases
2.3.1 Secondary Research
2.3.2 Primary Research
2.3.3 Econometric Modelling
2.3.4 Expert Validation
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By Drug Type
5.1.1 Antibiotic anticoccidials
5.1.2 Ionophore anticoccidials
5.1.3 Chemical derivative anticoccidials
5.2 By Animal Type
5.2.1 Poultry
5.2.2 Swine
5.2.3 Fish
5.2.4 Cattle
5.2.5 Companion Animal
6. Geographical Analysis
6.1 Introduction
6.2 U.K
6.3 Spain
6.4 Germany
6.5 Italy
6.6 France
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 Bayer Health care
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Zoetis
8.3 Elanco
8.4 Merck Animal Healthcare
8.5 Virbac
8.6 Ceva Santé Animale
8.7 Boehringer Ingelheim Animal Health
8.8 Novartis Animal Healthcare
8.9 Smartvet Inc.
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Expert Opinions
10.1 Market Outlook
10.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
